Search
Vaccines Treatment Options
A collection of 948 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
301 - 312 of 948
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
Terminated
This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by performing tests in the laboratory on participants' blood and tumor samples.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Melanoma
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Completed
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine. Allergic reactions range from mild to severe and include life- threatening anaphylactic reactions, although no deaths have been reported with either vaccine.
This study is designed with two principal aims:
* To estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine in a... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
11/30/2023
Locations: University of Arizona Health Sciences, College of Medicine Tucson, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Tucson, Arizona +28 locations
Conditions: SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Withdrawn
The purpose of this research is to investigate whether the combination of STING-dependent Adjuvants (STAVs) and dendritic cell (DC) vaccine therapies will increase the body's ability to fight aggressive relapsed or refractory leukemias.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: University of Miami, Miami, Florida
Conditions: Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Adult T-Cell Leukemia/Lymphoma
Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT
Active Not Recruiting
This is a single site, phase 1 study of dmLT as a mucosal adjuvant to control fecal viral shedding when used in combination with intradermally administered fractional dose trivalent IPV (fIPV). It will be a 2-arm, randomized, double-blind controlled trial of intradermal fIPV versus fIPV+dmLT in healthy adults with a monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity. A maximum of 30 healthy subjects will be recruited, all of whom will have received IPV only... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/28/2023
Locations: University of Vermont Vaccine Testing Center at the Larner College of Medicine, Burlington, Vermont
Conditions: Poliomyelitis
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
Completed
In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
11/28/2023
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Herpes Zoster
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Completed
Primary Objective:
To demonstrate sufficiency of the vaccine seroresponse to meningococcal serogroups A, C, W, and Y following administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine to Group 1 participants (who received primary vaccination with Menomune vaccine greater than or equal to \[\>= 3\] years earlier at \>= 56 years of age in Study MET49).
Secondary Objectives:
Secondary Objective 1 - To demonstrate s... Read More
Gender:
ALL
Ages:
59 years and above
Trial Updated:
11/27/2023
Locations: Investigational Site Number 8400026, Chandler, Arizona +33 locations
Conditions: Meningococcal Infection (Healthy Volunteers)
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
Active Not Recruiting
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Naval Medical Center San Diego, San Diego, California +8 locations
Conditions: Influenza, Influenza-like Illness, Influenza Vaccines
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
Completed
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that:
H1: Shingrix vaccination will elevate acute and trained immunity
H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
11/20/2023
Locations: Fran and Earl Ziegler College of Nursing, Oklahoma City, Oklahoma
Conditions: Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Completed
This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer. Vaccines made from peptide or antigen and/or a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express breast cancer antigens. It is not yet known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating patients with breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Breast Ductal Carcinoma In Situ
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Completed
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
11/13/2023
Locations: Children's of Alabama, Birmingham, Alabama +109 locations
Conditions: Pneumococcal Disease
Vaccine Response With NT-I7
Withdrawn
Background:
People with cancer, and especially older people, have a weakened immune system (the defense system of the body). This is often caused by the treatments for cancer. Older cancer survivors are therefore more prone to getting infections, some of which are preventable through vaccines. But because their immune systems are weakened, their response to vaccines is poor. Researchers want to see if a new drug, NT-I7, can help.
Objective:
To see if NT-I7 can boost the immune system.
Eligib... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different dose levels of messenger ribonucleic acid (mRNA) vaccine encoding influenza hemagglutinin compared to an active control quadrivalent recombinant influenza vaccine (RIV4) in adults 18 years of age and older. Study details include:
Study Duration: approximately 6 months Treatment Duration: 1 injection of mRNA vaccine encoding influenza hemagglutinin encoding influenza hemag... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Peninsula Research Associates Site Number : 8400013, Rolling Hills Estates, California +19 locations
Conditions: Influenza, Influenza Immunization
301 - 312 of 948